Patents Assigned to Rheinische Friedrich-Wilhelms-Universitat
  • Patent number: 10036021
    Abstract: The present invention provides an oligonucleotide which is capable of activating RIG-I and inducing an anti-viral, in particular, an IFN, response in cells expressing RIG-I. The present invention further provides an oligonucleotide which is capable of activating RIG-I and which has target gene-silencing activity. The oligonucleotide of the present invention has a double-stranded section of at least 19, preferably at least 21 bp, at least one 5? triphosphate, and at least one blunt end which bears a 5? triphosphate. The present invention further provides the use said oligonucleotide for inducing an anti-viral, in particular, an IFN, response in vitro and in vivo. The present invention additionally provides the use of said oligonucleotide for preventing and/or treating diseases or conditions such as infections, tumors/cancers, and immune disorders.
    Type: Grant
    Filed: May 10, 2016
    Date of Patent: July 31, 2018
    Assignee: Rheinische Friedrich-Wilhelms-Universität Bonn
    Inventors: Gunther Hartmann, Martin Schlee
  • Publication number: 20180177722
    Abstract: The present invention provides a formulation of Coenzyme Q10 that can be re-dispersed from a stable dry powder to formulation to yield a nano dispersion that can be readily aerosolized for inhalation.
    Type: Application
    Filed: June 24, 2016
    Publication date: June 28, 2018
    Applicants: STC.UNM, RHEINISCHE FRIEDRICH-WILHELMS-UNIVERSITAT BONN, BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Jason Thomas McConville, Thiago Carvalho, Kristina Schonhoff
  • Patent number: 9944721
    Abstract: The present invention relates to a branched or unbranched free or glycosidically bound polysialic acid according to general formula (1) as given as follows poly-(?(2?8 or 2?9)Neu5Ac)n (1) wherein Neu5Ac is N-acetylneuraminic acid, and n is an integer in the range from 14 to 26 and/or pharmaceutically acceptable salts thereof, a polysaccharide composition comprising the polysialic acid (1), and the use as a medicament, particularly in the therapeutic and/or prophylactic treatment of degenerative, demyelinating and inflammatory diseases of the central nervous system, and degenerative or inflammatory retinal diseases.
    Type: Grant
    Filed: March 18, 2014
    Date of Patent: April 17, 2018
    Assignees: RHEINISCHE FRIEDRICH-WILHELMS UNIVERSITÄT BONN, UNIVERSITÄT ZU KÖLN
    Inventors: Harald Neumann, Jens Kopatz, Anahita Shahraz, Marcus Karlstetter, Thomas Langmann
  • Patent number: 9910045
    Abstract: The present invention relates to a method of determining a protein in a sample and the use of the method for the identification of aptamer target proteins.
    Type: Grant
    Filed: September 7, 2016
    Date of Patent: March 6, 2018
    Assignee: RHEINISCHE FRIEDRICH-WILHELMS UNIVERSITAT BONN
    Inventors: Michael Famulok, Gunter Mayer, Jan Vinkenborg
  • Patent number: 9896689
    Abstract: The present invention relates to a method of preparing triphosphate-modified oligonucleotides using a capture tag. The method allows the synthesis and purification of triphosphate-modified oligonucleotides in high yield and purity suitable for pharmaceutical applications.
    Type: Grant
    Filed: June 10, 2016
    Date of Patent: February 20, 2018
    Assignee: Rheinische Friedrich-Wilhelms-Universität Bonn
    Inventors: Janos Ludwig, Marion Goldeck, Brian Sproat
  • Patent number: 9844522
    Abstract: The present invention relates to novel therapeutic uses of niclosamide for the treatment of cancer. In particular, a combination of niclosamide or one of its derivatives with an alkylating agent is provided for the treatment of solid tumors. Moreover, niclosamide or one of its derivatives can be used for the treatment of solid tumors characterized by underexpression of NFKBIA. Finally, the invention relates to diagnostic methods for determining whether treatment with niclosamide alone or in combination with an alkylating agent is suitable for a cancer patient.
    Type: Grant
    Filed: August 6, 2013
    Date of Patent: December 19, 2017
    Assignees: LIFE & BRAIN GMBH, RHEINISCHE FRIEDRICH-WILHELMS UNIVERSITAT BONN
    Inventors: Björn Scheffler, Martin Glas, Anja Wieland
  • Patent number: 9790507
    Abstract: The present invention relates to an aptamer comprising a nucleotide sequence SEQ ID NO: 1, a composition comprising an aptamer, and the use of the aptamer in the diagnosis and treatment of cancer, particularly solid tumors.
    Type: Grant
    Filed: May 26, 2014
    Date of Patent: October 17, 2017
    Assignee: RHEINISCHE FRIEDRICH-WILHELMS UNIVERSITÄT BONN
    Inventors: Günter Mayer, Ursula Maria Katia Schöler, Mohammad Seyed Taghdisi Heidarian
  • Patent number: 9738680
    Abstract: The present invention provides an oligonucleotide which is capable of activating RIG-I and inducing an anti-viral, in particular, an IFN, response in cells expressing RIG-I. The present invention further provides an oligonucleotide which is capable of activating RIG-I and which has target gene-silencing activity. The oligonucleotide of the present invention has a double-stranded section of at least 19, preferably at least 21 bp, at least one 5? triphosphate, and at least one blunt end which bears a 5? triphosphate. The present invention further provides the use said oligonucleotide for inducing an anti-viral, in particular, an IFN, response in vitro and in vivo. The present invention additionally provides the use of said oligonucleotide for preventing and/or treating diseases or conditions such as infections, tumors/cancers, and immune disorders.
    Type: Grant
    Filed: May 20, 2009
    Date of Patent: August 22, 2017
    Assignee: Rheinische Friedrich-Wilhelms-Universität Bonn
    Inventors: Gunther Hartmann, Martin Schlee
  • Patent number: 9573960
    Abstract: The present invention relates to glioblastoma inhibiting compounds, in particular gambogic acid amid and derivatives thereof for the treatment of glioblastoma. Moreover, methods for determining whether a treatment with the compounds of the invention is suitable for a patient are disclosed.
    Type: Grant
    Filed: June 15, 2012
    Date of Patent: February 21, 2017
    Assignees: Life & Brain GmbH, Rheinische Friedrich-Wilhelms Universitat
    Inventors: Björn Scheffler, Martin Glas, Matthias Simon, Sabine Gogolok, Daniel Trageser, Roman Reinartz, Anja Wieland
  • Patent number: 9409941
    Abstract: The present invention provides an oligonucleotide which is capable of activating RIG-I and inducing an anti-viral, in particular, an IFN, response in cells expressing RIG-I. The present invention further provides an oligonucleotide which is capable of activating RIG-I and which has target gene-silencing activity. The oligonucleotide of the present invention has a double-stranded section of at least 19, preferably at least 21 bp, at least one 5? triphosphate, and at least one blunt end which bears a 5? triphosphate. The present invention further provides the use said oligonucleotide for inducing an anti-viral, in particular, an IFN, response in vitro and in vivo. The present invention additionally provides the use of said oligonucleotide for preventing and/or treating diseases or conditions such as infections, tumors/cancers, and immune disorders.
    Type: Grant
    Filed: May 20, 2009
    Date of Patent: August 9, 2016
    Assignee: Rheinische Friedrich-Wilhelms-Universität Bonn
    Inventors: Gunther Hartmann, Martin Schlee
  • Patent number: 9399658
    Abstract: The present invention relates to a method of preparing triphosphate-modified oligonucleotides using a capture tag. The method allows the synthesis and purification of triphosphate-modified oligonucleotides in high yield and purity suitable for pharmaceutical applications.
    Type: Grant
    Filed: March 28, 2012
    Date of Patent: July 26, 2016
    Assignee: Rheinische Friedrich-Wilhelms-Universität Bonn
    Inventors: Janos Ludwig, Marion Goldeck, Brian Sproat
  • Patent number: 9381208
    Abstract: Oligonucleotides bearing free, uncapped 5? phosphate group(s) are recognized by RIG-I, leading to the induction of type I IFN, IL-18 and IL-1? production. Bacterial RNA also induces type I IFN production. 5? phosphate oligonucleotides and bacterial RNA can be used for inducing an anti-viral response or an anti-bacterial response, in particular, type I IFN and/or IL-18 and/or IL-1? production, in vitro and in vivo and for treating various disorders and diseases such as viral infections, bacterial infections, parasitic infections, tumors, allergies, autoimmune diseases, immunodeficiencies and immunosuppression. Single-stranded 5? triphosphate RNA can be used for inducing an anti-viral response, an anti-bacterial response, or an anti-tumor response, in particular, type I IFN and/or IL-18 and/or IL-1? production, in a target cell-specific manner.
    Type: Grant
    Filed: May 8, 2012
    Date of Patent: July 5, 2016
    Assignee: Rheinische Friedrich-Wilhelms-Universität
    Inventors: Gunther Hartmann, Veit Hornung
  • Publication number: 20160152983
    Abstract: The present invention relates to new triphosphate-modified oligonucleotides which may act as RIG-I ligands as well as a new method allowing the synthesis and purification in high yield and purity suitable for pharmaceutical applications.
    Type: Application
    Filed: September 26, 2013
    Publication date: June 2, 2016
    Applicant: RHEINISCHE FRIEDRICH-WILHELMS-UNIVERSITÄT BONN
    Inventors: Marion GOLDECK, Jasper VAN DEN BOORN, János LUDWIG, Christine SCHUBERTH-WAGNER
  • Publication number: 20160008460
    Abstract: In a first aspect, the present invention relates to the use of a TLR 9 agonist and/or a TLR 4 agonist in a prophylactic or therapeutic vaccine. According to the present vaccination strategy, the TLR 9 agonist and/or TLR 4 agonist is adapted or designed for use as a multiplying jump agent to enhance numbers and functionality of CD8 T cells in a prime-jump vaccination strategy for jump T cell expansion. In particular, the TLR 9 agonist and/or TLR 4 agonist is used as a component to be administered after priming of the individual to be vaccinated. The vaccination strategy is particularly useful against acute and chronic infections with intracellular pathogens or for anti-tumor vaccination. In another aspect, the present invention relates to a kit of part containing a prime agent and a multiplying jump agent according to the present invention.
    Type: Application
    Filed: February 25, 2014
    Publication date: January 14, 2016
    Applicants: RHEINISCHE FRIEDRICH-WILHELMS UNIVERSITÄT BONN, TECHNISCHE UNIVERSITÄT MÜNCHEN, HELMHOLTZ ZENTRUM MÜNCHEN DEUTSCHES FORSCHUNGSZENTRUM FÜR GESUNDHEIT UND UMWELT (GM
    Inventors: Percy Knolle, Li-Rung Huang, Mathias Heikenwälder, Ulrike Protzer
  • Publication number: 20150275217
    Abstract: The present invention relates to new triphosphate-modified oligonucleotides which may act as RIG-I ligands as well as a new method allowing the synthesis and purification in high yield and purity suitable for pharmaceutical applications.
    Type: Application
    Filed: March 27, 2015
    Publication date: October 1, 2015
    Applicant: RHEINISCHE FRIEDRICH-WILHELMS-UNIVERSITÄT BONN
    Inventors: Marion GOLDECK, Jasper VAN DEN BOORN, János LUDWIG, Christine SCHUBERTH-WAGNER
  • Patent number: 9103819
    Abstract: The present invention relates to a tumor cell of the peripheral zone of a tumor and methods of providing such a tumor cell. Further provided is a method for identifying a molecular marker diagnostic for an infiltrative cancer, an antibody, which specifically binds to such molecular marker, a method for identifying a therapeutic compound effective against a metastatic/infiltrative cancer disease and the use of a tumor cell according to the invention.
    Type: Grant
    Filed: September 9, 2009
    Date of Patent: August 11, 2015
    Assignee: Rheinische Friedrich-Wilhelms-Universität Bonn
    Inventors: Björn Scheffler, Matthias Simon, Oliver Brüstle, Ulrich Johannes Herrlinger, Martin Glas
  • Patent number: 9011862
    Abstract: The present invention relates to a method for identifying an inhibitor of the aggregation of amyloid-? peptide (A?), comprising the steps of a) contacting at least one A? -peptide and/or the nitrated forms thereof with at least one candidate inhibitor that potentially specifically binds to a region in said A? -peptide capable of being nitrated, and b) detecting said inhibitor specifically binding to said region in said A? -peptide through detecting a lack of or a reduced aggregation of said at least one A? -peptide. The present invention is further directed at improved methods for treating neuronal degradation and particularly Alzheimer's disease, based on said inhibitor. The present invention is further directed at methods for diagnosing the aggregation of A? -peptide in the context of neuronal degradation and particularly Alzheimer's disease.
    Type: Grant
    Filed: July 12, 2010
    Date of Patent: April 21, 2015
    Assignee: Rheinische Friedrich-Wilhelms-Universität Bonn
    Inventors: Michael Thomas Heneka, Markus Peter Kummer
  • Publication number: 20150057161
    Abstract: The invention is based on the finding of specific surface markers for M1-like (classically activated) and M2-like (alternatively activated) macrophages and provides for a method for the identification, characterization and isolation of M1-like and M2-like macrophages based on the abundance of said surface markers and for means for performing such method.
    Type: Application
    Filed: March 13, 2013
    Publication date: February 26, 2015
    Applicants: BECTON DICKINSON AND COMPANY, RHEINISCHE FRIEDRICH-WILHELMS-UNIVERSITÄT-BONN
    Inventors: Joachim Schultze, Michael Mallmann
  • Patent number: 8846645
    Abstract: The present invention relates to compounds according to general formula (I), pharmaceutical compositions comprising compounds according to general formula (I) and the use of the compounds for the treatment of a bacterial infection, particularly for use as an antibiotic.
    Type: Grant
    Filed: December 13, 2011
    Date of Patent: September 30, 2014
    Assignees: Rheinische Friedrich-Wilhelms Universität Bonn, Universität Konstanz
    Inventors: Günter Mayer, Christina Elsbeth Luense, Valentin Wittmann, Magnus S. Schmidt
  • Publication number: 20140288019
    Abstract: A phosphorylated A2A receptor agonist providing agonist properties on the A2A receptor after dephosphorylation the phosphorylated A2A receptor agonist comprises a ribosyl moiety and a purine moiety and being phosphorylated at the 5?-position of the ribose moiety except adenosine monophosphate (AMP), adenosine diphosphate (ADP) or adenosine triphosphate (ATP), a medicament containing the compound of the invention including ADP and the use of the compound of the invention including ATP and ADP for several medical indications e.g. inflammatory events. In particular, compounds of formula (I) are also disclosed.
    Type: Application
    Filed: December 16, 2013
    Publication date: September 25, 2014
    Applicants: Rheinische Friedrich-Wilhelms-Universitat Bonn, Heinrich-Heine- Universität Düsseldorf
    Inventors: Jurgen SCHRADER, Christa Muller, Ali El-Tayeb, Jamshed Iqbal